Drug – bio-affecting and body treating compositions – Identification or warning feature – Taste or smell or chemical irritation to the eye – nose – or...
Patent
1989-09-07
1992-01-21
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Identification or warning feature
Taste or smell or chemical irritation to the eye, nose, or...
514415, 514460, 514690, 514922, A61K 4500, A61K 31405, A61K 3135, A61K 3112
Patent
active
050826506
ABSTRACT:
The present invention comprises the serious side effect of mevinolin to depress body levels of coenzyme Q.sub.10 and to correspondingly depress cardiac function and the circumvention of this side effect by the clinical administration of a formulation of coenzyme Q.sub.10 concommitantly with the administration of the mevinolin.
REFERENCES:
patent: 4929437 (1990-05-01), Tobert
patent: 4933165 (1990-06-01), Brown
Alberts, et al. (1980), Proc. Natl. Acad. Sci. U.S.A., 77(7):3957-61.
Merck, Sharp and Dohme, publishers (1988), Product Monograph of Mevacor.RTM. (Lovastatin/MSD), pp. 1-77.
Dr. Emile G. Bliznakov and Gerald L. Hunt, The Miracle Nutrient Coenzyme Q.sub.10, Bantam Books, New York, New York, 1986, pp. 65-104 and pp. 220-232.
Folkers Karl A.
Langsjoen Per H.
Robinson Douglas W.
Witz Jean C.
LandOfFree
Amelioration of reductions of coenzyme Q.sub.10 in cardiomyopath does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amelioration of reductions of coenzyme Q.sub.10 in cardiomyopath, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amelioration of reductions of coenzyme Q.sub.10 in cardiomyopath will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-114322